Obexelimab, an investigational therapy for people with immunoglobulin G4-related disease (IgG4-RD), was found to reduce disease activity among participants in an IgG4-RD clinical study without eliminating the benefits of vaccination against flu and COVID-19, according to new data. Additional results from other analyses showed obexelimab can lessen the need…
Discussion
I recently attended a free webinar called “Prevail: Creating Your Path Forward with IgG4-RD,” sponsored by the pharmaceutical company Amgen. The speaker was rheumatologist Brittany Panico. What resonated with me most from her presentation was the variety of organs that are commonly affected by the disorder, the range of…
Discussion
Note: This column describes the author’s own experiences with various medications and therapies. Not everyone will have the same response to treatment. Consult your doctor before starting or stopping a therapy. September was supposed to be my month — not only because I was celebrating my birthday, but because I…
Get regular updates to your inbox.
